These results demonstrate that the combination of APG-2449 and paclitaxel effectively inhibits tumor growth in ovarian cancers with FAK overexpression or amplification by downregulating CD44+ and ALDH+ CSC populations. Here, CD44 is linked to ovarian cancer.